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Systemic Lupus Erythematosus (SLE) Induced by Quinidine
Carl J. Lavie, MD; Joseph Biundo, MD; Robert J. Quinet, MD; Jack Waxman, MD
\s=b\Only two definite cases of quinidine-induced systemic
lupus erythematosus (SLE) are reported in the English-lan-
guage literature. We have treated five patients who had an SLE\x=req-\
like syndrome while receiving quinidine. Symptoms, signs,
and abnormal laboratory values improved after quinidine ther-
apy was discontinued and prednisone therapy was started.
The disease did not return after steroids were withdrawn.
These cases indicate that quinidine can indeed cause an SLE\x=req-\
like syndrome.
(Arch Intern Med 1985;145:446-448)
lX/Tany commonly administered cardiovascular drugs, in-
" *" eluding procainamide hydrochloride, hydralazine hy-
drochloride, and phenytoin sodium, can induce antinuclear
antibodies (ANAs) and, occasionally, a syndrome resem¬
bling systemic lupus erythematosus (SLE).1 Quinidine,
however, is not listed in most tables of therapeutic agents
implicated in provoking SLE. We know of only two reported
cases in the English-language literature of quinidine-in-
duced SLE.2,3 In this study, we describe five patients who
had drug-induced SLE while receiving quinidine. Coagula¬
tion abnormalities, including thrombocytopenia, prolonged
prothrombin (PT) and partial thromboplastin (PTT) times,
and a factor IX (Christmas factor) deficiency developed in
one patient.
PATIENTS AND METHODS
Data were obtained from the records of five patients who had
clinical and laboratory evidence of SLE while receiving quinidine.
Four of the patients were seen at the Ochsner Foundation Hospital,
New Orleans, and one (patient 3) was seen at Louisiana State
University Medical Center, New Orleans. The patient records
were reviewed to determine the quinidine preparation used, the
duration of quinidine administration before the development of
symptoms, presenting symptoms and laboratory abnormalities,
response to therapy, and follow-up. These data are in Tables 1 and 2.
An illustrative report is provided below of one of the cases (case 1)
with quinidine-induced SLE, including extra-articular disease and
coagulation abnormalities.
REPORT OF A CASE
A 50-year-old man was seen at the Ochsner Foundation Hospital
with a one-day history of severe bilateral pleuritic chest pain and a
one-year history of severe proximal interphalangeal arthralgias in
both hands, with occasional pains in other joints. He had taken
several anti-inflammatory medications in the past and was re¬
ceiving a combination of choline and magnesium trisalicylates,
1,500 mg, twice daily. He had been receiving 300 mg of quinidine
sulfate four times daily for 18 months for a ventricular arrhythmia
that was diagnosed at another hospital.
Physical examination showed an oral temperature of 37.9 °C, a
systolic heart murmur, decreased bibasilar breath sounds with
bibasilar dullness to percussion, and hepatosplenomegaly.
Preliminary laboratory studies showed the following values:
WBCs, 7,700/cu mm, without a left shift; hemoglobin, 11.8 g/dL;
hematocrit, 36.3%, with normal indexes; normal electrolyte levels;
blood urea nitrogen, 19 mg/dL; creatinine, 1.9 mg/dL; glu¬
cose, 109 mg/dL; PT, 18.6 s patient/10.7 s control; PTT, 49.2 s
patient/34.2 s control; platelets, 77,000/cu mm; ESR (Westergren),
73 mm/hr; and reticulocytes, 3.9%. Arterial blood gases on room
air showed a pH of 7.42, Pco2 of 39 mm Hg, and Po2 of 65 mm Hg; on
2 L of oxygen by nasal cannula the pH was 7.45, Pco2 was
34 mm Hg, and the Po2 was 96 mm Hg. The ECG was normal, and
the chest roentgenogram showed bilateral pleural effusions that
proved to be inflammatory and sterile after pleural fluid was
obtained by thoracentesis. Ventilation-perfusion pulmonary scan
was not suggestive of pulmonary embolism; a liver-spleen scan
confirmed hepatosplenomegaly.
Additional laboratory studies revealed a creatinine clearance of
79 mL/min with normal urinary sediment. Iron levels of 30 µg/dL
with a total iron binding capacity of292 µg/dL were consistent with
iron deficiency anemia. Complement studies showed a C3 of
170 mg/dL (normal, 115 to 260 mg/dL) and C4 of 18 mg/dL (normal,
20 to 50 mg/dL). Clotting factor assays showed factor II to be 78%(normal, 50% to 150%), factor VIII more than 100%, and factor IX
was decreased at 30%. The patient's ANA was speckled and
nucleolar at a titer of 1/1,024 using rat liver substrate (normal, 1/16),
antibodies to double-stranded DNA and to histones were negative,
as were antibodies to SS- , SS-B, RNP, Scl-70, and SmAg. The
patient's blood was negative for lupus type and for circulating
anticoagulants.
Quinidine therapy was discontinued; prednisone therapy was
started at 60 mg/day. Recordings of 24-hour Holter ECG monitor¬
ing showed less ventricular ectopy after this drug was stopped than
recordings obtained during therapy with quinidine. Although the
patient's symptoms and laboratory abnormalities (elevated ESR,
thrombocytopenia, prolonged PT and PTT, and factor IX defi¬
ciency) all responded rapidly to quinidine withdrawal and steroid
administration, the ANA value dropped slowly. Steroids were
gradually discontinued over a three-month period. When steroids
were no longer being given, symptoms and laboratory abnormali¬
ties did not return, although the patient had transient arthralgias
for six months. Six months after steroids were stopped, the ANA
was positive at 1/128, and one year after steroid withdrawal the
ANA was 1/32. The patient has had no further problems with
arthralgias, pleuritis, or high-grade ventricular ectopy.
COMMENT
Quinidine is a type I antiarrhythmic drug that is useful
for atrial and ventricular arrhythmias. Toxic reactions and
troublesome side effects occur in about 40% of patients
receiving quinidine therapy. The most important side ef¬
fects are cardiovascular and include orthostatic hypoten¬
sion, increases in ventricular ectopie activity, asystole,
syncope, acceleration in ventricular rate, and impaired left
ventricular contractility. The most common side effect of
quinidine is gastrointestinal, especially diarrhea, although
anorexia, nausea, and vomiting are occasionally seen. Other
side effects include cinchonism, tinnitis, visual blurring,
confusion, low-grade fevers, cholestatic hepatitis, a lym-
phomalike syndrome, and multiple coagulopathies and
blood dyscrasias.4
Many cardiovascular drugs, including procainamide,
hydralazine, and phenytoin, induce a syndrome resembling
SLE,1 but quinidine is not listed in most tables of therapeu¬
tic agents implicated in provoking a lupuslike syndrome. In
fact, we know of only three published cases in the English-
language literature of SLE occurring in patients receiving
quinidine,2,3,5 although other reports are published in an¬
other language. The 1983 Physicians' Desk Reference
contains no mention of an SLE-like syndrome for quinidine
sulfate or quinidine polygalacturonate, but under quinidine
gluconate it says, "Although extremely rare, there have
been reports of lupus erythematosus in patients taking
quinidine. A positive association with quinidine therapy has
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*QID indicates four times daily; TID, three times daily; BID, twice a day; and SR, slow release.
not been established."6
Kendall and Hawkins,6 in 1970, described a 73-year-old
woman who had dermatitis, lymphadenopathy, hepato-
splenomegaly, hemolytic anemia, leukopenia, thrombocy-
topenia, and a positive antinuclear factor after taking
1.2 g/day of quinidine for two years. The patient's disease
was controlled on low-dose prednisone, but it was impossi¬
ble to discontinue quinidine therapy. Therefore, one cannot
be certain that this patient's SLE was induced by quinidine.
Anderson and Wanerka,2 in 1972, described a 10-year-old
girl who was seen with epistaxis and thrombocytopenia
after receiving 200 mg of quinidine gluconate twice daily for
three years. The patient also had fever, rash, hepatic
involvement, pericardial friction rub, a positive direct
Coombs' test, a positive LE cell preparation, and a strongly
positive antinuclear factor. Although the systemic illness
resolved and the LE cell preparation became negative soon
after quinidine therapy was discontinued, the antinuclear
factor remained positive six years later.
Finally, Yudis and Meehan,3 in 1976, described a 49-year-
old woman who had polyarthritis, leukopenia, a positive
ANA test, and signs of lupus nephropathy with a positive
urinary sediment, diminished creatinine clearance, and
decreased serum complement after receiving 200 mg of
quinidine sulfate four times daily for three months. The case
is unique for two reasons. First, the ANA test became
negative shortly after quinidine therapy was stopped. Also,
nephropathy is unusual in cases of drug-induced SLE.
Neither conversion of the ANA test to negative nor signs of
nephropathy occurred in the other two published cases or in
the cases presented herein.
We described five patients (four men and one woman) who
had an SLE-like syndrome while receiving quinidine (Table
1). Two of the patients had been receiving quinidine sulfate,
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two were receiving quinidine gluconate, and one received
quinidine polygalacturonate. All five patients were seen
with polyarthritis, elevated ESRs, strongly positive tests
for ANAs, and negative tests for antibodies to double-
stranded DNA. One of the patients also had pleuritis with
inflammatory pleural effusions and coagulation abnormali¬
ties.
An undetermined ANA was found in patients taking
quinidine. Most cases of drug-induced SLE have antibodies
to histones with homogeneous ANA patterns and do not
have antibodies to double-stranded (native) DNA.7 Al¬
though none of the patients had antibodies to double-
stranded DNA, four of the five patients had speckled
ANAs. Three of those four patients were tested and found
to have no antibodies to histones or to SS- , SS-B, RNP,
Scl-70, or SMAg. Patient 5 initially had a homogeneous
ANA when he was first seen with a procainamide-induced
lupus. The patient became asymptomatic one month after
stopping procainamide therapy and remained asympto¬
matic for eight months. His ANA titer dropped from 1/512 to
1/64. A lupuslike syndrome developed eight months after
starting quinidine therapy, and the ANA converted to a
speckled pattern at a titer of 1/1,024. Patient 3 initially had a
homogeneous ANA titer that later converted to speckled
and has remained speckled six years later. Because patient
4 was receiving methyldopa, which is reported to cause an
SLE-like syndrome,8 there is no way to know whether
quinidine or methyldopa caused the lupus. The case is
included here, nevertheless, because the patient had been
taking methyldopa for more than five years, but the syn¬
drome developed only eight months after he began receiv¬
ing quinidine. The patient also had speckled ANAs, as did
three of the four other patients presented in this report.
The index case (case 1) demonstrated coagulation abnor¬
malities that can be caused by quinidine. These include
thrombocytopenia, prolonged PT and PTT, and a factor IX(Christmas factor) deficiency. Thrombocytopenia occurs in
about 3% of patients receiving quinidine and is thought to
be due to antibodies to platelet-quinidine complexes.
Quinidine is also known to cause hypoprothrombinemia and
to potentiate the anticoagulant effects ofwarfarin sodium.4,6
We are unaware of any reports in the English-language
literature of quinidine prolonging the PTT or causing a
factor IX deficiency, although this is described in the non-
English literature.9,10
Each of the five patients in this article was withdrawn
from quinidine therapy and treated with tapering doses of
oral prednisone (Table 2). The reason for using cortico-
steroids in the first patient with significant extra-articular
disease manifested by pleuritis and inflammatory pleural
effusions and coagulation abnormalities seems self-evident.
Many patients with drug-induced lupus caused by other
agents, particularly procainamide and hydralazine, im¬
prove with drug withdrawal and do not require cortico-
steroid therapy. The patients described herein, however,
were debilitated by their polyarthritis and required more
aggressive therapy than many patients with drug-induced
lupus syndromes. Prednisone was started at doses of 10 to
15 mg/day in all patients except in the one patient with
extra-articular disease who received 60 mg/day, and
steroids were tapered over six to 12 weeks. In one patient,
steroids were restarted several times during a 16-month
period because of exacerbations in lower extremity pain
that was actually thought to be due to peripheral neuropa¬
thy. After quinidine withdrawal and short-term steroid
therapy, symptoms slowly resolved in all five patients and
did not return after steroids were withdrawn. Laboratory
abnormalities also improved, although low titers of ANAs
remained positive in the five patients. Symptoms have not
returned in patients followed up for 1.5 to seven years.
Only one of the five patients described in this article
requires antiarrhythmic therapy now. In fact, three pa¬
tients had the same amount of ventricular ectopy both while
receiving and not receiving quinidine. One patient had less
ventricular ectopy after quinidine was stopped. It is well
known that antiarrhythmic drugs, particularly quinidine,
may aggravate or even induce ventricular arrhythmia.11
Therapy for high-grade malignant ventricular ectopy is
controversial and is being reevaluated.12 Many patients,
including some in this article, are receiving toxic antiar¬
rhythmic agents without evidence of high-grade malignant
ventricular ectopy.
We believe the cases presented show that quinidine-
induced SLE, although rare, does indeed occur. Drug-
induced SLE and SLE are frequently indistinguishable
syndromes. None of the five patients in this report had
evidence of rheumatologic disease before receiving quini¬
dine, and symptoms and laboratory abnormalities devel¬
oped only after the administration of quinidine. Finally, and
perhaps most importantly, complete resolution of the SLE
occurred after quinidine therapy was discontinued, al¬
though low titers of ANAs have persisted in all five pa¬
tients. Whether quinidine induces the formation of ANAs
de novo or merely increased titers in patients who already
have low titers of ANAs was unanswered in this article.
Only one patient in this series was tested for ANAs long
after the syndrome had resolved. Iri this patient the ANA
test remained positive six years later, but the patient was
requiring antiarrhythmic therapy with phenytoin, which
can induce ANA formation.1 The other four patients were
not followed up long enough to determine if their ANAs
would disappear, but three of these patients and one patient
described in the literature2 had positive ANA tests more
than a year after quinidine therapy was discontinued.
Prospective studies are needed to determine the incidence
of quinidine-induced ANA formation and a lupuslike syn¬
drome. Also, the type of ANA associated with quinidine is
yet to be determined. Long-term follow-up would be helpful
to determine if ANAs completely disappear in any of the
patients described herein, and to assure that disease
flares never occur long after the quinidine has been
stopped.
Full case reports of patients 2 through 5 are available from the authors on
request.
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